Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (37)

2024

  1. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204

  2. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  3. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

2023

  1. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

    Journal of Thoracic Oncology, Vol. 18, Núm. 12, pp. 1731-1742

2022

  1. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5

  2. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645

  3. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer

    Cancer, Vol. 128, Núm. 9, pp. 1801-1811

  4. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800

2021

  1. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

    European Journal of Cancer, Vol. 151, pp. 211-220

2019

  1. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

    The Lancet Oncology, Vol. 20, Núm. 8, pp. 1109-1123

2018

  1. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

    European Respiratory Journal

  2. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase Ib Results

    Clinical Lung Cancer, Vol. 19, Núm. 3, pp. 213-220.e4

2017

  1. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer

    Lung Cancer, Vol. 108, pp. 212-216

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

  3. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non–Small-Cell Lung Cancer

    Clinical Lung Cancer, Vol. 18, Núm. 1, pp. 96-99

2015

  1. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer

    PLoS ONE, Vol. 10, Núm. 3

2013

  1. Phase i study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors

    Cancer Chemotherapy and Pharmacology, Vol. 72, Núm. 1, pp. 75-83

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

  2. Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function

    Medical Oncology, Vol. 29, Núm. 3, pp. 2240-2250

  3. Recommendations for the optimal management of early and advanced urothelial carcinoma

    Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441